AbbVie has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) and SKYRIZI (risankizumab, 150 mg) to the US Food and Drug Administration (FDA) and the European Medicines
The post AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis appeared first on Pharmaceutical Business review.